These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32778514)

  • 1. Durable Long-Term Response in a Patient With Diffuse Large B-Cell Lymphoma Treated With Nivolumab.
    Ginnaram SR; Mason EF; Reddy NM
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e934-e936. PubMed ID: 32778514
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab.
    Sandoval-Sus JD; Brahim A; Khan A; Deutsch Y; Raphael B; Ansari-Lari A; Fernandez HF; Raez LE
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):e113-e117. PubMed ID: 32033930
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab-caused hyperprogression of diffuse large B-cell lymphoma of the testis and spontaneous remission of type 2 diabetes mellitus in an elderly patient: a case report.
    Zhang X; Jiang D; Huang F; Wang Z; Jin H; Cui Y; Fan S
    Anticancer Drugs; 2021 Jun; 32(5):575-579. PubMed ID: 33595946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
    J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.
    Rogers KA; Huang Y; Dotson E; Lundberg J; Andritsos LA; Awan FT; Woyach JA; Byrd JC
    Br J Haematol; 2019 Apr; 185(2):363-366. PubMed ID: 30028000
    [No Abstract]   [Full Text] [Related]  

  • 6. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
    Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
    Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postallogeneic transplantation progressive multifocal leukoencephalopathy successfully treated by nivolumab.
    Uzunov M; Demeret S; Nguyen-Quoc S; Morel V; Bellanger A; Chavez H; Gasnault J; Leblond V; Roos-Weil D
    Br J Haematol; 2020 Mar; 188(6):e82-e84. PubMed ID: 31797364
    [No Abstract]   [Full Text] [Related]  

  • 8. Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy.
    Panariello L; Fattore D; Annunziata MC; Piantedosi F; Gilli M; Fabbrocini G
    Eur J Cancer; 2018 Nov; 103():284-286. PubMed ID: 30268391
    [No Abstract]   [Full Text] [Related]  

  • 9. Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.
    Ikeda T; Yamaguchi H; Dotsu Y; Taniguchi H; Gyoutoku H; Senju H; Sakamoto N; Iwanaga S; Kuwatsuka Y; Fukuda M; Mukae H
    Thorac Cancer; 2018 Nov; 9(11):1522-1524. PubMed ID: 30253076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
    AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
    Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    Komatsu T; Nakamura K; Kawase A
    J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
    [No Abstract]   [Full Text] [Related]  

  • 12. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum-Resistant Ovarian Cancer.
    Inayama Y; Hamanishi J; Matsumura N; Murakami R; Abiko K; Yamaguchi K; Baba T; Horie K; Konishi I; Mandai M
    Oncologist; 2018 Nov; 23(11):1382-1384. PubMed ID: 30158286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
    Khunger M; Velcheti V
    J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
    [No Abstract]   [Full Text] [Related]  

  • 15. Nivolumab for the Treatment of Advanced Pediatric Malignancies.
    MarjaŃska A; Drogosiewicz M; Dembowska-BagiŃska B; PawiŃska-WĄsikowska K; Balwierz W; Bobeff K; MŁynarski W; Mizia-Malarz A; Raciborska A; Wysocki M; StyczyŃski J
    Anticancer Res; 2020 Dec; 40(12):7095-7100. PubMed ID: 33288608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    Funazo T; Nomizo T; Kim YH
    J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
    [No Abstract]   [Full Text] [Related]  

  • 17. Nivolumab for the treatment of colorectal cancer.
    Smith KM; Desai J
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.
    Ishihara H; Kondo T; Takagi T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Tanabe K
    Target Oncol; 2018 Oct; 13(5):611-619. PubMed ID: 30232691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
    Raggi D; Necchi A; Giannatempo P
    Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.